The race to develop even more effective obesity drugs is heating up.
People who stayed on this dose lost around 20% of their baseline weight over a 72 week period.
The findings exceed the typical weight loss results seen with the existing semaglutide-based drugs Ozempic and Wegovy.
An Ozempic injection pen.© Jaap Arriens/NurPhoto via Getty
Semaglutide mimics the hormone GLP-1, which helps regulate our hunger and metabolism.
Its the active ingredient in key in 2 diabetes drug Ozempic and the higher-dose obesity drug Wegovy.
Since Wegovys FDA approval in 2021, Ozempic has often been prescribed off-label for weight loss.
And both Novo Nordisk and its competitors have made efforts to develop the next generation of these drugs.
Just as importantly, the higher dose version of semaglutide appeared to be generally safe and tolerable.
Much more rarely, scientists have linked GLP-1 drugs to severe complications likegastroparesis(stomach paralysis).
But even its highest-dose version is expected to face stiff competition.
Other obesitydrugs in developmenthave also shown early, but promising results that might overshadow both tirzepatide and semaglutide.
Another consideration is cost.
The future of obesity treatment is looking bright, but its also going to be costly.
News from the future, delivered to your present.
You May Also Like
Trump Is Promising to Lower Drug Prices.
Does Ozempic Really Cause Thyroid Cancer?
